Mutational complexity increases in lung adenocarcinoma (LADC) with the development of brain metastasis (BM).
暂无分享,去创建一个
S. Kesari | S. Phuphanich | A. Brenner | A. Heimberger | S. Mittal | W. Korn | Deepa S. Subramaniam | Manjari Pandey | Mike G Martin | S. Michelhaugh | A. Sumrall | Matthew K Stein | J. Xiu | A. Provenzano | Matthew K. Stein
[1] J. Szustakowski,et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.
[2] J. Marshall,et al. Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients , 2018, Cancer medicine.
[3] Ahmet Zehir,et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Peters,et al. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. , 2016, Cancer treatment reviews.
[5] H. Hansen,et al. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.